ZURICH, April 20 (Reuters) - Switzerland's drug regulator is
still awaiting data needed to consider AstraZeneca's
COVID-19 vaccine candidate for approval, a Swissmedic official
said on Tuesday, adding the information "unfortunately" has yet
to be submitted.
"We're waiting, just like the U.S. Food and Drug
Administration, for the results of clinical trials in Latin
America and North America," Claus Bolte, Swissmedic's head of
approvals said at a virtual press conference from Bern. "It was
announced four weeks ago, but it has unfortunately not yet been
submitted."
(Reporting by John Miller, editing by John Revill)